CCDC6 and non-small cell lung carcinoma: In selected NSCLC, vandetanib (300 mg/day) was tested in a Japanese phase II study (LURET) including 17 RET-rearranged NSCLC patients, 31% of whom were CCDC6-RET-positive, 53% were KIF5B-RET-rearranged, 16% had an unknown RET status [91].